CBER chief Peter Marks (Jim Lo Scalzo/Pool via AP Images)
May 19, 2023 11:28 AM EDTUpdated May 25, 08:08 AM
Cell/Gene Tx
FDA+

CBER chief Pe­ter Marks to con­sid­er 'al­ter­na­tives' to clin­i­cal holds as they 'put shud­ders down in­vestors' spines'

Zachary Brennan

Senior Editor

As mem­bers of the House ex­pressed con­cerns with the num­ber of clin­i­cal holds at Pe­ter Marks’ Cen­ter for Bi­o­log­ics Eval­u­a­tion and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Bris­tol My­er­s' schiz­o­phre­nia drug fails Phase 3 tri­al for ad­junc­tive treat­ment

Chi­na’s biotech mar­ket is stag­ing a come­back that US biotech can on­ly wish for

As­cle­tis posts puz­zling Phase 1 up­date on obe­si­ty pill

Genen­tech vet launch­es ADC start­up with $20M

With aims to be­come a 'gen­er­a­tional biotech,' Zealand Phar­ma hires Lil­ly vet­er­an as sci­ence chief

sponsored

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

A service from the Financial Times